Imbria Pharmaceuticals
Imbria Pharmaceuticals raises $57.5M Series B at $350M valuation
Imbria Pharmaceuticals: Series B Funding Round
Imbria Pharmaceuticals has successfully raised $57.5M in Series B funding, reaching a valuation of $350M.
Company Overview
Cardiomyopathy therapeutics
Funding Details
The Series B round was led by Deep Track Capital, with participation from RA Capital.
Company Information
- Headquarters: Boston, MA
- Founded: 2018
- Employees: 60+
- Category: HealthTech
Investment
Imbria Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deep Track Capital: Verified investor in Series B
- RA Capital: Verified investor in Series B
Company Info
Investors (2)
Share
Related Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free